CN109937033A - 用于药物递送的具有渗透增强剂的组合物 - Google Patents

用于药物递送的具有渗透增强剂的组合物 Download PDF

Info

Publication number
CN109937033A
CN109937033A CN201780069720.5A CN201780069720A CN109937033A CN 109937033 A CN109937033 A CN 109937033A CN 201780069720 A CN201780069720 A CN 201780069720A CN 109937033 A CN109937033 A CN 109937033A
Authority
CN
China
Prior art keywords
composition
penetration enhancer
certain embodiments
combination
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780069720.5A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼尔·S·克哈奈克
杨蓉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Children's Hospital
Original Assignee
Boston Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Children's Hospital filed Critical Boston Children's Hospital
Priority to CN202510689336.1A priority Critical patent/CN120392650A/zh
Publication of CN109937033A publication Critical patent/CN109937033A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780069720.5A 2016-09-14 2017-09-14 用于药物递送的具有渗透增强剂的组合物 Pending CN109937033A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510689336.1A CN120392650A (zh) 2016-09-14 2017-09-14 用于药物递送的具有渗透增强剂的组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394716P 2016-09-14 2016-09-14
US62/394,716 2016-09-14
PCT/US2017/051577 WO2018053140A1 (en) 2016-09-14 2017-09-14 Compositions with permeation enhancers for drug delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510689336.1A Division CN120392650A (zh) 2016-09-14 2017-09-14 用于药物递送的具有渗透增强剂的组合物

Publications (1)

Publication Number Publication Date
CN109937033A true CN109937033A (zh) 2019-06-25

Family

ID=61619716

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780069720.5A Pending CN109937033A (zh) 2016-09-14 2017-09-14 用于药物递送的具有渗透增强剂的组合物
CN202510689336.1A Pending CN120392650A (zh) 2016-09-14 2017-09-14 用于药物递送的具有渗透增强剂的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510689336.1A Pending CN120392650A (zh) 2016-09-14 2017-09-14 用于药物递送的具有渗透增强剂的组合物

Country Status (8)

Country Link
US (1) US20200138710A1 (enExample)
EP (1) EP3512501A4 (enExample)
JP (1) JP7277360B2 (enExample)
KR (1) KR20190053215A (enExample)
CN (2) CN109937033A (enExample)
AU (1) AU2017326347B2 (enExample)
CA (1) CA3036696A1 (enExample)
WO (1) WO2018053140A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118518439A (zh) * 2023-02-17 2024-08-20 清华大学 离子液体制剂和组织处理方法及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016304585B2 (en) 2015-08-05 2023-04-06 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery
WO2022031577A1 (en) * 2020-08-03 2022-02-10 Children's Medical Center Corporation Thermo-sensitive permeation enhancing formulations for drug delivery
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts
GB202100945D0 (en) * 2021-01-25 2021-03-10 Brightcure Ltd A composition useful for treating bacterial infections
DE102021132055B4 (de) 2021-10-08 2024-12-12 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mit beschränkter Haftung Neue Therapiekonzepte für die Behandlung von Otitis
CN117618338A (zh) * 2022-08-16 2024-03-01 海南普利制药股份有限公司 一种稳定的奥利万星药物水溶液及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006597A1 (en) * 1994-08-30 1996-03-07 Alcon Laboratories, Inc. Thermally-gelling ophthalmic drug delivery vehicles containing cellulose ethers
US6316011B1 (en) * 1998-08-04 2001-11-13 Madash, Llc End modified thermal responsive hydrogels
US20040141949A1 (en) * 2000-11-22 2004-07-22 Rosenthal Gary J. Treatment of mucositis
US20070098772A1 (en) * 2005-09-23 2007-05-03 Westcott Tyler D Transdermal norelgestromin delivery system
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
WO2010074992A2 (en) * 2008-12-22 2010-07-01 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
AU2016304585B2 (en) * 2015-08-05 2023-04-06 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006597A1 (en) * 1994-08-30 1996-03-07 Alcon Laboratories, Inc. Thermally-gelling ophthalmic drug delivery vehicles containing cellulose ethers
US6316011B1 (en) * 1998-08-04 2001-11-13 Madash, Llc End modified thermal responsive hydrogels
US20040141949A1 (en) * 2000-11-22 2004-07-22 Rosenthal Gary J. Treatment of mucositis
US20070098772A1 (en) * 2005-09-23 2007-05-03 Westcott Tyler D Transdermal norelgestromin delivery system
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
WO2010074992A2 (en) * 2008-12-22 2010-07-01 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUNTER RL ET AL.: "Enhancement of Antibiotic Susceptibility and Suppression of Mycobacterium avium Complex Growth by Poloxamer 331", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118518439A (zh) * 2023-02-17 2024-08-20 清华大学 离子液体制剂和组织处理方法及其应用

Also Published As

Publication number Publication date
WO2018053140A1 (en) 2018-03-22
US20200138710A1 (en) 2020-05-07
CN120392650A (zh) 2025-08-01
KR20190053215A (ko) 2019-05-17
EP3512501A1 (en) 2019-07-24
CA3036696A1 (en) 2018-03-22
JP2019533644A (ja) 2019-11-21
AU2017326347B2 (en) 2023-07-20
AU2017326347A1 (en) 2019-03-21
JP7277360B2 (ja) 2023-05-18
EP3512501A4 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
US12053527B2 (en) Compositions with permeation enhancers for drug delivery
JP7277360B2 (ja) 薬物送達のための透過促進剤を有する組成物
JP7033789B2 (ja) トリグリセリド耳用製剤とその使用
US11123286B2 (en) Auris formulations for treating otic diseases and conditions
CN110420211A (zh) 治疗炎症、自身免疫性疾病和疼痛的方法
TW202034900A (zh) 有關耳用治療劑之醫藥組成物及方法
JP2024170397A (ja) 薬物送達のための相乗的な透過促進剤を伴う組成物
US20230270749A1 (en) Thermo-sensitive permeation enhancing formulations for drug delivery
TWI412370B (zh) 用於治療耳疾病及症狀的耳配方
HK40006438A (en) Triglyceride otic formulations and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190625

RJ01 Rejection of invention patent application after publication